WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has received 510(k) clearance for its ADVANCE System (“ADVANCE”) from the U.S. Food and Drug Administration (FDA). This regulatory determination by the FDA gives NeuroMetrix clearance to market ADVANCE in the U.S. market. The device is intended to be used by physicians to perform nerve conduction studies and invasive electromyography procedures.
